KA/EN
Register
Medicines reference
Search
Search
Product

Maropitant Bioveta

Favourites

Maropitant · Bioveta a.s.

1 form: solution. In force in Georgia: 1 of 1 (veterinary register).

Forms and doses1 of 1 in force in Georgia

The dose from the product's label, by species and weight. Check the label of the pack you use.

Choose species and weight; the matching row will be highlighted.
Form Species Dose Frequency Georgia
10 mg/ml, Solution · Cat Cat 1 mg/kg
1 mg/kg (1 ml per 10 kg) under the skin or into a vein once a day for up to 5 days. To prevent vomiting give more than 1 hour before. Injection under the skin can sting.
 · once daily, up to 5 days		 once daily, up to 5 days Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: მაროპიტანტი ბიოვეტა 10მგ/მლ
Verified on: 22 Oct 2026
10 mg/ml, Solution · Dog Dog 1 mg/kg
1 mg/kg (1 ml per 10 kg) under the skin or into a vein once a day for up to 5 days. To prevent vomiting give more than 1 hour before. Injection under the skin can sting.
 · once daily, up to 5 days		 once daily, up to 5 days Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: მაროპიტანტი ბიოვეტა 10მგ/მლ
Verified on: 22 Oct 2026
Details: pack, label wording, sources, registration

Maropitant Bioveta 10 mg/ml, Solution

maropitant 10 mg/ml, solution for injection for dogs and cats
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Label-concordant SC/IV prevention and treatment of vomiting, chemotherapy-associated nausea and defined perioperative nausea/vomiting roles in dogs, with cause-directed supportive care
8.0/10
Very good
vetman assessment

Maropitant Bioveta

10 mg/ml, maropitant 10 mg/ml, solution for injection for dogs and cats
Assessed clinical scopeDog · Label-concordant SC/IV prevention and treatment of vomiting, chemotherapy-associated nausea and defined perioperative nausea/vomiting roles in dogs, with cause-directed supportive care · SC,IV
Care settingVeterinary assessment with cause-directed diagnostics and supportive care; clinic-administered SC or undiluted IV bolus, route chosen for patient comfort/access, with response and hydration monitoring
vetman score 8.0/10 Very good
Evidence confidence: Medium Georgia: Yes, veterinary · Verified on 22 Oct 2026

A strong, transparent generic maropitant injection with robust reference-product antiemetic evidence and a practical once-daily regimen. It controls vomiting, not its cause, and SC pain plus hepatic/cardiac/interaction limits still matter.

Regulatory and scientific credibility8.5/10

The exact transparent 10 ml dog/cat SC/IV product has a current multi-country EU generic authorisation explicitly linked to Cerenia, a current official product leaflet and Georgian registration. Exact-Bioveta independent outcome or pharmacovigilance data are limited, so reference-product transfer remains visible.

Clinical efficacy8.5/10

Large multicentre placebo-controlled and European comparative field trials show strong reduction of acute vomiting across diverse canine causes, while label and reference-product evidence support chemotherapy and perioperative roles. It remains symptomatic treatment, excludes injectable motion-sickness use and must not delay diagnosis or source control.

Safety and tolerability7.0/10

The therapeutic margin is generally good and most adverse effects are local/transient, but SC pain is very common. Hepatic accumulation, cardiac ion-channel caution, protein-binding interactions, age/reproductive uncertainty and rare anaphylactoid or neurologic reactions require selection and monitoring.

Clinical practicality8.0/10

Once-daily 0.1 ml/kg dosing, SC/IV choice, 24-hour effect and up-to-five-day course are highly workable in clinic. SC sting, exact undiluted IV bolus/no-mixing instruction, 20-puncture limit and 28-day vial life add manageable route and wastage checks.

Full-course cost-effectiveness-

Current Georgian full-course price and vial-wastage data were unavailable; price is excluded from the denominator.

Important safety and use flags

  • Antiemesis is symptomatic care. Vomiting can signal gastrointestinal obstruction, toxin exposure or severe systemic disease; complete appropriate diagnostics, hydration/diet support and cause-directed treatment.
  • The injectable label excludes motion-sickness vomiting. Do not transfer the higher-dose tablet motion-sickness regimen to this 10 mg/ml injection.
  • Give 1 mg/kg (0.1 ml/kg) SC or IV once daily for no more than five consecutive days. For prevention administer more than one hour before the trigger; do not redose early because effect is expected for about 24 hours.
  • SC injection pain is very common in dogs. Cooling may reduce the sting; use appropriate restraint and consider IV when access and clinical circumstances favour it.
  • For IV use, follow the exact Bioveta instruction: administer as a single undiluted bolus and do not mix with other fluids or veterinary medicines because compatibility has not been established.
  • Do not use with hypersensitivity to maropitant or any excipient. Safety is unestablished below 8 weeks in dogs, below 16 weeks in cats, and during pregnancy/lactation; use only after an explicit veterinarian benefit–risk assessment.
  • Use cautiously in hepatic disease and monitor liver function and adverse effects with repeated/prolonged exposure; nonlinear metabolism can produce accumulation. Do not extend beyond the labelled five consecutive days without a new evidence-based plan.
  • Use cautiously with cardiac disease or predisposition. Do not give with calcium-channel antagonists; maropitant is highly protein-bound and can compete with other highly bound medicines.
  • Stop and treat suspected anaphylactoid reaction. Rare lethargy, ataxia, convulsions/seizures or muscle tremor are reported; continued vomiting despite treatment warrants immediate diagnostic reassessment rather than automatic repeat dosing.
  • Use the vial for no more than 20 stopper punctures and discard 28 days after first opening. Avoid self-injection and skin/eye contact; accidental exposure can cause nausea, dizziness, somnolence or irritation and needs medical advice.
Assessment sources
  1. Bioveta EU generic2025
  2. Bioveta exact leaflet
  3. Cerenia VMD control2024
  4. Cerenia FDA control2025
  5. Dog maropitant RCT2008
  6. Dog European field trial2007
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Label-concordant SC/IV prevention and treatment of vomiting and reduction of nausea in cats, excluding motion sickness and with cause-directed supportive care
7.6/10
Good
vetman assessment

Maropitant Bioveta

10 mg/ml, maropitant 10 mg/ml, solution for injection for dogs and cats
Assessed clinical scopeCat · Label-concordant SC/IV prevention and treatment of vomiting and reduction of nausea in cats, excluding motion sickness and with cause-directed supportive care · SC,IV
Care settingVeterinary assessment with cause-directed diagnostics and supportive care; clinic-administered SC or undiluted IV bolus, route chosen for patient comfort/access, with response and hydration monitoring
vetman score 7.6/10 Good
Evidence confidence: Medium Georgia: Yes, veterinary · Verified on 22 Oct 2026

A well-supported antiemetic with a transparent generic dossier and strong feline emesis prevention, but not guaranteed nausea relief. Frequent painful SC reactions make IV or careful pain-reduction planning important.

Regulatory and scientific credibility8.5/10

The exact transparent 10 ml dog/cat SC/IV product has a current multi-country EU generic authorisation explicitly linked to Cerenia, a current official product leaflet and Georgian registration. Exact-Bioveta independent outcome or pharmacovigilance data are limited, so reference-product transfer remains visible.

Clinical efficacy8.0/10

Reference-product field data and controlled feline PK/induced-emesis studies strongly support 1 mg/kg SC/IV antiemesis for about 24 hours. Vomiting reduction is consistent, but nausea behaviours may persist despite suppression of emesis and evidence across spontaneous causes is less extensive than in dogs.

Safety and tolerability6.5/10

Systemic tolerability is generally good, but moderate/severe SC injection reaction occurs in about one third of cats and adult-cat overdose evidence is absent. Hepatic/cardiac caution, age and reproductive limits, interactions and rare anaphylactoid or neurologic reactions remain clinically important.

Clinical practicality7.0/10

Once-daily weight-based dosing and an IV option are practical, but marked feline SC pain may require IV access or cooling/restraint and materially affects welfare. The undiluted bolus/no-mixing rule, small-volume accuracy, 20-puncture limit and 28-day vial life need active workflow control.

Full-course cost-effectiveness-

Current Georgian full-course price and vial-wastage data were unavailable; price is excluded from the denominator.

Important safety and use flags

  • Antiemesis is symptomatic care. Vomiting can signal gastrointestinal obstruction, toxin exposure or severe systemic disease; complete appropriate diagnostics, hydration/diet support and cause-directed treatment.
  • The injectable label excludes motion-sickness vomiting. Do not transfer the higher-dose tablet motion-sickness regimen to this 10 mg/ml injection.
  • Give 1 mg/kg (0.1 ml/kg) SC or IV once daily for no more than five consecutive days. For prevention administer more than one hour before the trigger; do not redose early because effect is expected for about 24 hours.
  • SC injection pain is very common and is moderate or severe in about one third of cats. Consider an appropriately cooled vial and low-stress restraint or use IV when clinically appropriate; do not dismiss the reaction as bad behaviour.
  • For IV use, follow the exact Bioveta instruction: administer as a single undiluted bolus and do not mix with other fluids or veterinary medicines because compatibility has not been established.
  • Do not use with hypersensitivity to maropitant or any excipient. Safety is unestablished below 8 weeks in dogs, below 16 weeks in cats, and during pregnancy/lactation; use only after an explicit veterinarian benefit–risk assessment.
  • Use cautiously in hepatic disease and monitor liver function and adverse effects with repeated/prolonged exposure; nonlinear metabolism can produce accumulation. Do not extend beyond the labelled five consecutive days without a new evidence-based plan.
  • Use cautiously with cardiac disease or predisposition. Do not give with calcium-channel antagonists; maropitant is highly protein-bound and can compete with other highly bound medicines.
  • Stop and treat suspected anaphylactoid reaction. Rare lethargy, ataxia, convulsions/seizures or muscle tremor are reported; continued vomiting despite treatment warrants immediate diagnostic reassessment rather than automatic repeat dosing.
  • Use the vial for no more than 20 stopper punctures and discard 28 days after first opening. Avoid self-injection and skin/eye contact; accidental exposure can cause nausea, dizziness, somnolence or irritation and needs medical advice.
Assessment sources
  1. Bioveta EU generic2025
  2. Bioveta exact leaflet
  3. Cerenia VMD control2024
  4. Cerenia FDA control2025
  5. Feline maropitant PK efficacy2008
  6. Feline SC maropitant RCT2016
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Maropitant10 mg/ml
Formulation Type
Solution
Administration route
Subcutaneous, Intravenous
Manufacturer
Bioveta a.s. · Czechia
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: მაროპიტანტი ბიოვეტა 10მგ/მლ
Verified on: 22 Oct 2026
 EU Yes, veterinary
№ CZ/V/0192/001
Verified on: 22 Oct 2026
 UK No
Verified on: 22 Oct 2026
 US No
Verified on: 22 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Information not fully verified Dogs and cats: 1 mg/kg (0.1 ml/kg; 1 ml/10 kg) SC or IV once daily for no more than five consecutive days. For prevention, administer more than one hour before the emetogenic trigger; effect lasts about 24 hours. Exact Bioveta IV instruction is a single bolus without mixing with other fluids. Do not use the injectable motion-sickness tablet schedule. The vial may be punctured at most 20 times and is discarded 28 days after first opening.
DoseSpeciesWeightRouteFrequencySource
1 mg/kg
1 mg/kg (1 ml per 10 kg) under the skin or into a vein once a day for up to 5 days. To prevent vomiting give more than 1 hour before. Injection under the skin can sting.
 Cat Any weight SC,IV once daily, up to 5 days
Bioveta EU generic
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Maropitant Bioveta 10 mg/ml solution for injection - current EU generic authorisation record
EU Veterinary Medicines Information / Union Product Database, 2025
1 mg/kg
1 mg/kg (1 ml per 10 kg) under the skin or into a vein once a day for up to 5 days. To prevent vomiting give more than 1 hour before. Injection under the skin can sting.
 Dog Any weight SC,IV once daily, up to 5 days
Bioveta EU generic
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Maropitant Bioveta 10 mg/ml solution for injection - current EU generic authorisation record
EU Veterinary Medicines Information / Union Product Database, 2025

Known Contraindications

  • Warning
    Maropitant is metabolised in the liver and therefore should be used with caution in patients with hepatic disease. As maropitant is accumulated in the body during a 14 day treatment period due to metabolic saturation, careful monitoring of liver function and any adverse events should be implemented during long term treatment.
    Sources: VMD SPC · VMD
  • Warning
    The veterinary medicinal product should be used with caution in animals suffering from or with predisposition for cardiac diseases as maropitant has affinity to Ca- and K-ion channels.
    Sources: VMD SPC · VMD
  • Warning
    Vomiting can be associated with serious, severely debilitating conditions including gastrointestinal obstructions; therefore, appropriate diagnostic evaluations should be employed.
    Sources: VMD SPC · VMD
  • Warning
    Use only according to the benefit-risk assessment by the responsible veterinarian, because conclusive reproductive toxicity studies have not been conducted in any animal species.
    Sources: VMD SPC · VMD
  • Warning
    The safety of maropitant has not been established in... pregnant or lactating dogs and cats.
    Sources: VMD SPC · VMD
  • Warning (Dog)
    The safety of maropitant has not been established in dogs less than 8 weeks of age, or in cats less than 16 weeks of age.
    Sources: VMD SPC · VMD
  • Warning (Cat)
    The safety of maropitant has not been established in dogs less than 8 weeks of age, or in cats less than 16 weeks of age.
    Sources: VMD SPC · VMD

Known Drug Interactions

  • Major warning Amlodipine + Maropitant
    The veterinary medicinal product should not be used concomitantly with Ca-channel antagonists as maropitant has affinity to Ca-channels.
    Recommendation: None
    Sources: VMD SPC · VMD

Products are connected by name, active ingredients, or therapeutic group. They are not direct substitutes for one another.

Show all related products (41 more) Hide additional products

Same therapeutic group 41

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 23 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗